Intelligence · Clinical Pipeline

Anaxis Pharma Pipeline

All ClinicalTrials.gov programs at Anaxis Pharma — phase, modality, and trial IDs.

Programs
223

Quick answer

Anaxis Pharma has 223 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. Terbinafin "Moberg Pharma", kutanopløsning, Terbinafina Moberg Pharma 98 mg/mL soluzione cutanea, Terbinafina Moberg Pharma 98 mg/mL soluzione cutanea, Terclara, kutanopløsning, Terbinafina Moberg Pharma 98 mg/mL soluzione cutanea

    Lacuna Pharma Pty Ltd

    Distal Subungual Onychomycosis

    phase 2 small molecule active

    1 trial
  2. The corresponding placebo solution consists of the 25 nM phosphate buffer solution with 4 μg of vitamin B2 added for colouring purposes only., RBD1016, Vemlidy 25 mg film-coated tablets.

    Lacuna Pharma Pty Ltd

    Chronic hepatitis D virus infection

    phase 2 small molecule active

    1 trial
  3. The placebo is the same as the ensifentrine suspension except that the active ensifentrine ingredient is omitted (i.e., it consists of phosphate buffered saline and surfactants only); it is also supplied as a single unit-dose LDPE translucent ampule overwrapped in a foil pouch, Ensifentrine inhalation suspension

    Lacuna Pharma Pty Ltd

    Non-Cystic Fibrosis Bronchiectasis

    phase 2 small molecule active

    1 trial
  4. The placebo will consist solely of the excipients of eblasakimab, i.e., the same formulation without the active ingredient and will be identical in appearance to eblasakimab. Pharmaceutical form: Solution for SC injection

    Lacuna Pharma Pty Ltd

    Atopic Dermatitis

    phase 2 small molecule active

    1 trial
  5. Thiogamma 600 mg Filmtabletten, Benfogamma Forte, 300 mg, tabletki powlekane

    Lacuna Pharma Pty Ltd

    Diabetic sensorimotor polyneuropathy (DSPN)

    phase 2 small molecule active

    1 trial
  6. Tovinontrine, Tovinontrine, Tovinontrine, tovinontrine-matching placebo, immediate-release tablet

    Lacuna Pharma Pty Ltd

    Heart failure (HF) with reduced ejection fraction (HFrEF)

    phase 2 small molecule active

    1 trial
  7. Tovorafenib, Tovorafenib

    Lacuna Pharma Pty Ltd

    RAF-Altered, Recurrent or Progressive Low-Grade Glioma and Advanced Solid Tumors in pediatric patients

    phase 2 small molecule active

    1 trial
  8. TransCon CNP 3.9 mg CNP-38/vial, Placebo for TransCon CNP

    Lacuna Pharma Pty Ltd

    Achondroplasia in Children and Adolescents

    phase 2 small molecule active

    1 trial
  9. TransCon CNP, Placebo for TransCon CNP

    Lacuna Pharma Pty Ltd

    Achondroplasia in Children and Adolescents

    phase 2 small molecule active

    1 trial
  10. TransCon IL-2 ß/ү, TransCon TLR7/8 Agonist, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Lacuna Pharma Pty Ltd

    Stage III-IVA Resectable Locoregionall Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)

    phase 2 small molecule active

    1 trial
  11. TransCon TLR7/8 Agonist, TransCon IL-2 ß/ү, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Lacuna Pharma Pty Ltd

    Locally advanced or metastatic solid tumor malignancies, platinum resistant ovarian cancer, post-anti-pd-1 melanoma, second line or later cervical cancer, neoadjuvant melanoma and neoadjuvant non-small cell lung cancer, post-anti-pd-L1 non-small cell lung cancer, post-anti-pd-L1 small cell lung cancer, second line or later HER2+ breast cancer

    phase 2 small molecule active

    1 trial
  12. TransCon hGH, TransCon hGH, TransCon CNP

    Lacuna Pharma Pty Ltd

    Children with Achondroplasia

    phase 2 small molecule active

    1 trial
  13. Ubamatamab, TOCILIZUMAB, Ubamatamab, Kevzara 175 mg/ml solution for injection, CEMIPLIMAB, LIBTAYO 350 mg concentrate for solution for infusion., Sarilumab

    Lacuna Pharma Pty Ltd

    Fallopian Tube Cancer, Endometrial Cancer, Ovarian Cancer, Primary Peritoneal Cancer

    phase 2 small molecule active

    1 trial
  14. VANCOMYCIN , MaaT013

    Lacuna Pharma Pty Ltd

    Gastrointestinal Acute Graft-versus-Host Disease (GI-aGvHD)

    phase 2 small molecule active

    1 trial
  15. VDA-1102, VDA-1102 placebo

    Lacuna Pharma Pty Ltd

    Actinic keratosis

    phase 2 small molecule active

    1 trial
  16. VENETOCLAX, VENETOCLAX, SY-1425, VENETOCLAX, AZACITIDINE

    Lacuna Pharma Pty Ltd

    RARA-positive acute myeloid leukemia

    phase 2 small molecule active

    1 trial
  17. Vehicle to TOP-N53, TOP-N53, Sildenafil Teva 20 mg filmomhulde tabletten

    Lacuna Pharma Pty Ltd

    Digital ulcers in systemic sclerosis

    phase 2 small molecule active

    1 trial
  18. Vi-Siblin S granulat, alli 60 mg hard capsules, Dietary fibre supplement Placebo - Maltodextrin

    Lacuna Pharma Pty Ltd

    Obesity

    phase 2 small molecule active

    1 trial
  19. Vidaza 25 mg/ml powder for suspension for injection, Venclyxto 100 mg film-coated tablets, Venclyxto 10 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Venclyxto 10 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Venclyxto 100 mg film-coated tablets

    Lacuna Pharma Pty Ltd

    Acute Myeloid Leukaemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML)

    phase 2 small molecule active

    1 trial
  20. Vipoglanstat, The placebo formulation for GS-248 is formulated in a capsule without the active ingredient. Both vipoglanstat capsules and placebo are identical capsules.

    Lacuna Pharma Pty Ltd

    Endometriosis related pain

    phase 2 small molecule active

    1 trial
  21. Vonafexor

    Lacuna Pharma Pty Ltd

    Alport Syndrome

    phase 2 small molecule active

    1 trial
  22. Vonafexor, ROSUVASTATIN , IOHEXOL , Vonafexor

    Lacuna Pharma Pty Ltd

    Impaired renal function and suspected MASH

    phase 2 small molecule active

    1 trial
  23. YESCARTA 0.4 – 2 x 10e8 cells dispersion for infusion, Tecartus 0.4 - 2 x 10e8 cells dispersion for infusion, KITE-363

    Lacuna Pharma Pty Ltd

    Solid and Hematological Malignancies

    phase 2 small molecule active

    1 trial
  24. ZADAXIN® 1,6 mg/ml

    Lacuna Pharma Pty Ltd

    Cystic Fibrosis

    phase 2 small molecule active

    1 trial
  25. alpha 1H, Placebo product for Alpha1H

    Lacuna Pharma Pty Ltd

    Non-muscle invasive bladder cancer awaiting transurethral surgery

    phase 2 small molecule active

    1 trial
  26. bimekizumab

    Lacuna Pharma Pty Ltd

    Moderate to Severe Plaque Psoriasis

    phase 2 small molecule active

    1 trial
  27. non-preserved sterile liquid formulation

    Lacuna Pharma Pty Ltd

    Type 2 diabetes and Obesity

    phase 2 small molecule active

    1 trial
  28. phosphate buffered saline., FX06

    Lacuna Pharma Pty Ltd

    Acute Respiratory Distress Syndrome (ARDS)

    phase 2 small molecule active

    1 trial
  29. sotatercept, PL1 - Powder for injection

    Lacuna Pharma Pty Ltd

    Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) due to Heart Failure with Preserved Ejection Fraction (HFpEF)

    phase 2 small molecule active

    1 trial
  30. tamuzimod, tamuzimod, tamuzimod, VTX002 placebo film-coated tablets matching VTX002, tamuzimod

    Lacuna Pharma Pty Ltd

    Moderately to Severely Active Ulcerative Colitis

    phase 2 small molecule active

    1 trial
  31. tovinontrine-matching placebo, immediate-release tablet, Tovinontrine

    Lacuna Pharma Pty Ltd

    chronic heart failure

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many pipeline programs does Anaxis Pharma have?

223 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs